Many pharmaceutical drugs against neurological and cardiovascular disorders exert their therapeutic effects by binding to specific sites on voltage-gated ion channels of neurons or cardiomyocytes. To date, all molecules targeting known ion channel sites bind to protein pockets that are mainly surrounded by water. We describe a lipid-protein drug-binding pocket of a potassium channel. We synthesized and electrophysiologically tested 125 derivatives, analogs, and related compounds to dehydroabietic acid. Functional data in combination with docking and molecular dynamics simulations mapped a binding site for small-molecule compounds at the interface between the lipid bilayer and the transmembrane segments S3 and S4 of the voltage-sensor domain. This fundamentally new binding site for small-molecule compounds paves the way for the design of new types of drugs against diseases caused by altered excitability.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5656419PMC
http://dx.doi.org/10.1126/sciadv.1701099DOI Listing

Publication Analysis

Top Keywords

binding site
8
site small-molecule
8
small-molecule compounds
8
drug pocket
4
pocket lipid
4
lipid bilayer-potassium
4
bilayer-potassium channel
4
channel interface
4
interface pharmaceutical
4
pharmaceutical drugs
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!